IGF-1 LR3 Dosage Calculator, Benefits & Side Effects

As a lyophilized (freeze-dried) peptide, IGF-1 LR3 is generally reported to remain stable for 12-24 months when kept frozen (around -20°C), protected from light and moisture. Once reconstituted (commonly with bacteriostatic water, added slowly down the vial wall rather than directly onto the powder, then swirled gently — not shaken), the solution should be refrigerated at 2-8°C and is typically described as usable within about 2-4 weeks. Repeated freeze-thaw cycles and storage above refrigerator temperature are commonly cited as causes of peptide degradation and aggregation.

Both are derived from the IGF1 gene but act very differently. IGF-1 LR3 resists IGFBP binding and produces sustained, systemic IGF-1 receptor stimulation lasting many hours. MGF, by contrast, is a splice variant that the body naturally produces locally and transiently in mechanically stressed muscle tissue (e.g., after resistance exercise), with a much shorter window of activity focused on satellite cell activation near the site of muscle damage. In short: IGF-1 LR3 is discussed as a longer-acting, systemic signal, while MGF is discussed as a short-lived, localized one.

IGF-1 LR3 is not FDA-approved for human use and cannot legally be marketed or sold as a supplement or drug for human consumption. It is generally sold by research-chemical suppliers labeled 'for laboratory/research use only, not for human consumption,' which is the primary lawful sales channel. It is also explicitly banned in competitive sport — the World Anti-Doping Agency (WADA) prohibits IGF-1 and its analogs under its list of peptide hormones and growth factors. Any use in humans falls outside its intended research purpose and outside regulatory approval.

In bodybuilding and research-chemical forums, IGF-1 LR3 is frequently discussed alongside growth hormone secretagogues (e.g., GHRPs or GH releasing peptides) or anabolic compounds, based on the rationale that GH raises endogenous IGF-1 production while IGF-1 LR3 acts more directly and briefly at the receptor level. These combinations are discussed anecdotally in online communities and are not supported by controlled human studies establishing safety or effectiveness; stacking multiple substances that affect glucose regulation and growth signaling compounds the uncertainty and potential risk involved.